Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

NVAX Apr 19 '24 5.00 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Novavax to Participate in Jefferies London Healthcare Conference PR Newswire - Wed Nov 12, 7:00AM CST

GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference:

NVAX : 6.73 (+0.15%)
Novavax: Q3 Earnings Snapshot AP - Thu Nov 6, 7:19AM CST

Novavax: Q3 Earnings Snapshot

NVAX : 6.73 (+0.15%)
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire - Thu Nov 6, 7:00AM CST

GAITHERSBURG, Md. , Nov. 6, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025.

NVAX : 6.73 (+0.15%)
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment PR Newswire - Tue Nov 4, 6:00AM CST

GAITHERSBURG, Md. , Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling...

NVAX : 6.73 (+0.15%)
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire - Thu Oct 30, 7:00AM CDT

GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern...

NVAX : 6.73 (+0.15%)
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy PR Newswire - Wed Oct 22, 6:00AM CDT

GAITHERSBURG, Md. , Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model...

NVAX : 6.73 (+0.15%)
Novavax Transfers EU Vaccine Rights to Sanofi Tipranks - Wed Oct 8, 6:40AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax (...

NVAX : 6.73 (+0.15%)
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment PR Newswire - Tue Oct 7, 6:00AM CDT

GAITHERSBURG, Md. , Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European...

NVAX : 6.73 (+0.15%)
Novavax Announces Progress on Sanofi Agreement PR Newswire - Tue Sep 30, 8:01AM CDT

GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement  (CLA) with Sanofi regarding...

NVAX : 6.73 (+0.15%)
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment PR Newswire - Thu Sep 4, 7:00AM CDT

GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's...

NVAX : 6.73 (+0.15%)
More news for this symbol

NVAX Related stocks

Symbol Latest 3M %Chg
NVAX 6.72 -23.47%
Novavax Inc
AZN 91.94 +20.16%
Astrazeneca Plc ADR
AMGN 327.31 +16.17%
Amgen Inc
GILD 122.74 +10.77%
Gilead Sciences Inc
VRTX 453.36 +16.03%
Vertex Pharmaceutic
BMY 53.94 +20.01%
Bristol-Myers Squibb Company

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot